HM Sanchinarro
- Address
- Calle Ona 10, Madrid, Spain
EGFR Exon20 Insertion NSCLC Therapy
The oncology team at HM Sanchinarro is evaluating a novel targeted agent for patients with locally advanced or metastatic non‑small cell lung cancer that carries an EGFR exon‑20 insertion mutation. The study aims to compare anti‑tumor activity against standard platinum‑based chemotherapy.
- Assess anti‑tumor efficacy of the investigational drug
- Compare outcomes with platinum‑based doublet chemotherapy
- Focus on treatment‑naïve patients
Findings could expand therapeutic options for this genetically defined lung cancer subgroup.
Immunotherapy Combination for Advanced Epithelial Tumors (NG‑641)
Researchers are testing the safety of NG‑641 together with a PD‑1 inhibitor such as nivolumab in people with metastatic or advanced epithelial tumours. The early‑phase trial seeks to identify a tolerable dose and gather initial efficacy signals.
- Characterise safety and tolerability of the combination
- Determine recommended dose for further development
- Include patients with diverse epithelial cancer types
Successful results would support continued investigation of this novel immunotherapy pairing.
Immunotherapy Combination for Advanced Epithelial Tumors (NG‑350A)
A separate study examines NG‑350A in combination with pembrolizumab for individuals with metastatic or advanced epithelial tumours. The primary goal is to establish safety, tolerability, and an appropriate dose for future trials.
- Assess safety profile of NG‑350A plus pembrolizumab
- Identify optimal dosing for subsequent research
- Target a broad range of epithelial cancers
This work aims to broaden immunotherapeutic strategies for patients with hard‑to‑treat cancers.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Akamis Bio Limited2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 567 other sites in Spain
Therapeutic Area Benchmark — Spain
Select a therapeutic area to compare against other sites in Spain.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Spain
Market Share
Country: Spain
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in HM Sanchinarro
lock Showing 1 of 3 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Phase 1 Evaluation of NG-350A and Pembrolizumab in Patients with Metastatic or Advanced Epithelial Tumors | Akamis Bio Limited | Phase I | Not Recruiting | — | Dec 2023 |
IMP list
lock Showing 1 of 5 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 2 | Unknown | — | — |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.